AMPE – Ampio Pharmaceuticals Inc

Not Compliant

The company’s impure earnings are more than 5% of its total revenues.

Biotechnology & Medical Research
NYSE MKT

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The Company is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.

AAOIFI ✗

Debt ÷ Market cap (MC)

✓

Non-Compliant Assets ÷ MC

Impure Income (incl. Interest)

5.91

✗

Impure Income	%
Interest Income	5.91%
Total	5.91%

Found the Stock You’re Looking For? Open an Account Today!

Opening an account has never been easier! Please fill out the form here and an advisor will be in touch to walk you through the process!

Still have some further questions?